Zoetis Inc. reported full year (FY) 2025 revenue of USD 9.5 billion, reflecting a 6 percent increase. Adjusted net income for the period reached USD 2.8 billion, up 7 percent, while adjusted diluted earnings per share $(EPS)$ rose 10 percent to USD 6.41. Key product highlights for the year included the Simparica franchise, which grew 12 percent with double-digit growth in both the U.S. and international markets. Simparica Trio remained the leading canine parasiticide globally, surpassing USD 1 billion in U.S. sales and driving category expansion through innovation and retail initiatives. The company’s key dermatology franchise also delivered a 6 percent revenue increase, supported by a broad and differentiated portfolio. For the fourth quarter (Q4) of 2025, Zoetis posted revenue of USD 2.23 billion. Zoetis issued 2026 guidance with projected revenue between USD 9.83 billion and USD 10.03 billion, adjusted net income between USD 2.98 billion and USD 3.03 billion, and adjusted diluted EPS in the range of USD 7.00 to USD 7.10. The company expects organic revenue growth of 3 to 5 percent and adjusted net income growth of 3 to 6 percent for the year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zoetis Inc. published the original content used to generate this news brief on February 12, 2026, and is solely responsible for the information contained therein.